share_log

Clarivate (NYSE:CLVT) Given New $14.00 Price Target at Morgan Stanley

Clarivate (NYSE:CLVT) Given New $14.00 Price Target at Morgan Stanley

Clarivate(纽约证券交易所股票代码:CLVT)给予摩根士丹利14.00美元的新目标价
Financial News Live ·  2022/10/01 03:52

Clarivate (NYSE:CLVT – Get Rating) had its target price lowered by Morgan Stanley from $15.00 to $14.00 in a research report report published on Tuesday, Marketbeat reports. The firm currently has an overweight rating on the stock.

据市场报道,在周二发布的一份研究报告中,摩根士丹利将Clarivate(纽约证券交易所代码:CLVT-GET评级)的目标价从15.00美元下调至14.00美元。该公司目前对该股的评级为增持。

Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company initiated coverage on shares of Clarivate in a report on Tuesday, July 12th. They issued an overweight rating and a $20.00 price target for the company. Royal Bank of Canada cut their price target on shares of Clarivate from $23.00 to $18.00 and set an outperform rating for the company in a report on Friday, July 1st. Finally, TheStreet raised shares of Clarivate from a d+ rating to a c rating in a report on Tuesday, May 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $16.50.

其他股票研究分析师最近也发布了有关该股的报告。富国银行在7月12日星期二的一份报告中启动了对Clarivate股票的报道。他们为该公司发布了增持评级和20.00美元的目标价。加拿大皇家银行在7月1日星期五的一份报告中将Clarivate的股票目标价从23.00美元下调至18.00美元,并为该公司设定了表现优于大盘的评级。最后,华尔街在5月31日星期二的一份报告中将Clarivate的股票评级从d+上调至c。两名研究分析师对该股的评级为持有,四名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该股目前的平均评级为中等买入,平均目标价为16.50美元。

Get
到达
Clarivate
克拉里弗
alerts:
警报:

Clarivate Stock Performance

明晰股票表现

Shares of CLVT opened at $9.39 on Tuesday. The firm has a 50-day moving average price of $12.24 and a 200 day moving average price of $14.01. The firm has a market capitalization of $6.32 billion, a PE ratio of -46.95 and a beta of 0.89. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 0.56. Clarivate has a 52-week low of $9.06 and a 52-week high of $25.63.

周二,CLVT的股价开盘报9.39美元。该公司的50日移动均线价格为12.24美元,200日移动均线价格为14.01美元。该公司市值为63.2亿美元,市盈率为-46.95,贝塔系数为0.89。该公司的速动比率为0.82,流动比率为0.82,债务权益比为0.56。Clarivate的52周低点为9.06美元,52周高位为25.63美元。

Clarivate (NYSE:CLVT – Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.02. Clarivate had a net margin of 1.87% and a return on equity of 5.47%. The firm had revenue of $686.60 million during the quarter, compared to analyst estimates of $691.51 million. On average, sell-side analysts anticipate that Clarivate will post 0.7 earnings per share for the current fiscal year.
Clarivate(纽约证券交易所代码:CLVT-GET Rating)最近一次公布收益结果是在8月9日星期二。该公司公布本季度每股收益(EPS)为0.19美元,比分析师普遍预期的0.17美元高出0.02美元。Clarivate的净利润率为1.87%,股本回报率为5.47%。该公司本季度营收为6.866亿美元,而分析师预期为6.9151亿美元。卖方分析师平均预计,Clarivate本财年每股收益将为0.7%。

Insider Buying and Selling at Clarivate

Clarivate的内部买入和卖出

In related news, Director Andrew Miles Snyder purchased 208,333 shares of Clarivate stock in a transaction dated Wednesday, September 14th. The stock was acquired at an average cost of $11.61 per share, with a total value of $2,418,746.13. Following the completion of the transaction, the director now directly owns 208,333 shares of the company's stock, valued at $2,418,746.13. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 24.88% of the company's stock.

在相关新闻中,董事安德鲁·迈尔斯·斯奈德在一笔日期为9月14日(星期三)的交易中购买了208,333股Clarivate股票。收购该股票的平均成本为每股11.61美元,总价值为2,418,746.13美元。交易完成后,董事现在直接持有该公司208,333股股票,价值2,418,746.13美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可以通过美国证券交易委员会网站。内部人士持有该公司24.88%的股份。

Institutional Trading of Clarivate

Clarivate的机构交易

Hedge funds have recently made changes to their positions in the stock. Swiss National Bank increased its holdings in Clarivate by 13.9% in the first quarter. Swiss National Bank now owns 1,524,100 shares of the company's stock worth $25,544,000 after buying an additional 186,400 shares during the last quarter. Toronto Dominion Bank increased its holdings in Clarivate by 8.6% in the first quarter. Toronto Dominion Bank now owns 75,353 shares of the company's stock worth $1,263,000 after buying an additional 5,945 shares during the last quarter. Diversified Trust Co increased its holdings in Clarivate by 10.4% in the first quarter. Diversified Trust Co now owns 37,820 shares of the company's stock worth $634,000 after buying an additional 3,575 shares during the last quarter. TownSquare Capital LLC acquired a new position in Clarivate in the first quarter worth approximately $349,000. Finally, Robeco Institutional Asset Management B.V. acquired a new position in Clarivate in the first quarter worth approximately $154,000. 83.42% of the stock is owned by hedge funds and other institutional investors.

对冲基金最近对其股票头寸进行了调整。瑞士国家银行第一季度增持Clarivate股份13.9%。瑞士国家银行现在持有1,524,100股该公司股票,价值25,544,000美元,上个季度又购买了186,400股。多伦多道明银行第一季度增持Clarivate 8.6%。多伦多道明银行现在持有该公司75,353股股票,价值1,263,000美元,上个季度又购买了5,945股。多元化信托公司在第一季度增持了10.4%的Clarivate。多元化信托公司目前持有37,820股该公司股票,价值634,000美元,此前该公司在上个季度又购买了3,575股。Townsquare Capital LLC在第一季度收购了Clarivate的一个新头寸,价值约349,000美元。最后,Robeco Institution Asset Management B.V.在第一季度收购了Clarivate的一个新头寸,价值约15.4万美元。83.42%的股票由对冲基金和其他机构投资者持有。

Clarivate Company Profile

创建公司简介

(Get Rating)

(获取评级)

Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs.

Clarivate Plc是一家信息服务和分析公司,为科学研究、创新和品牌的发现、保护和商业化提供结构化信息和分析。它向计划、资助、实施和利用研究的组织提供科学网产品和服务,如科学网、INCITES、期刊引文报告、EndNote、ScholarOne、Converis、Publons和Kopnio;为制药和生物技术公司提供生命科学产品,包括Corellis和Newport Integrity,以支持与新药开发和商业化相关的研究、市场情报和竞争监测。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Clarivate (CLVT)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Thor Industries Hammers Out A Bottom
  • How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
  • 免费获取StockNews.com关于Clarivate的研究报告(CLVT)
  • 电动汽车电池制造商Freyr将在全球大举扩张
  • MarketBeat:回顾一周9/26-9/30
  • 这是买入美光科技的难忘时刻
  • 雷神工业走出谷底
  • Keurig Dr Pepper与规模更大的竞争对手可口可乐(Coke&Pepsi)相比如何?

Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.

接受Clarivate Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Clarivate和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发